Our analyses of existing clinical datasets for expression and survival outcomes show that KPNA2 over-expression contributes to poor patient survival outcomes, further necessitating its investigation in future studies to consider its clinical utility for triple negative breast cancer subtypes. This evidence concerns the gene KPNA2 and triple-negative breast carcinoma.